Chronic obstructive pulmonary disease (COPD) is a significant public health concern in the Indian subcontinent, with high prevalence rates observed in countries like India, Pakistan, Bangladesh, and neighboring nations. This review article critically examines the occupational risks associated with COPD in the region and emphasizes the need for comprehensive preventive strategies. The review begins by providing background on COPD and highlighting its impact on individuals and the economy. It then explores the different occupational hazards that contribute to the development and progression of COPD, including exposure to airborne pollutants and chemicals, occupational dust, and smoking and secondhand smoke in the workplace. The existing occupational health and safety regulations in the Indian subcontinent are assessed, along with an evaluation of their effectiveness in addressing occupational risks for COPD. The review also highlights gaps and challenges in implementing and enforcing these regulations. The impact of COPD on occupational health and the economy is examined, emphasizing the burden it places on affected individuals and their ability to work. The economic implications of COPD-related productivity losses are evaluated, underscoring the importance of addressing occupational risks to improve workforce health and productivity. Prevention and mitigation strategies are explored, including an overview of preventive measures to reduce occupational risks for COPD, the significance of early detection and diagnosis of COPD in the workplace, and the implementation of engineering controls, personal protective equipment, and ventilation systems. The role of education and training programs for workers and employers is also discussed. The review identifies research gaps in the current understanding of occupational risks and COPD in the Indian subcontinent and suggests future research directions to address these gaps. It emphasizes the importance of collaborative efforts between researchers, policymakers, and industry stakeholders to generate evidence, inform policy decisions, and implement effective interventions.

Atrial Fibrillation is very common among Americana; it is the irregular rhythm of the heart usually present with or without symptoms. It causes the formation of clots, clots go to the brain and cause a stroke. Anticoagulants have been known for a few decades to cause abrupt decrease around 50%) in the rate of stroke and prevent clotting at the required location and can cause bleeding. Anticoagulants aims for the safeguard and therapy of thromboembolism to prevent stroke. Previously used Anticoagulants are Warfarin, low molecular weight heparin and heparin. There were shortcoming of the drugs like parenteral route of administration, requires frequent monitoring due to variability in response, the onset of action is slow and there is bleeding in response to the drugs .In addition to heparin and vitamin k antagonist, anticoagulants that act on enzymatic agility or vigor brought about by of thrombin and factor Xa was exquisitely formulated. Implementation of the foresaid oral Anticoagulants requires knowledge of necessitate the comprehension of discrete indication, contraindications, characteristics. Research and repeated clinical trials have led to acceptance of few newer drugs which are working classically styled but better than Warfarin. In the last few years, Pradaxa (dabigatran), Xarelto (rivaroxaban), and Eliquis (dabigatran) have all been authorised by the FDA (apixaban). All three are ‘blood thinners,’ like warfarin, that lessen the overall risk of stroke associated with atrial fibrillation while also causing bleeding.